Vascular Access Catheters Market Size Projected to Rise Lucratively during 2027

With healthy CAGR of 5.5%, the global vascular access catheters market is likely to grow with an impressive growth rate during the projected period. The primary reasons for this remarkable growth is shift towards value-based healthcare model, increasing global healthcare spending and global manufacturer’s focus on emerging market. According to the new report “Vascular Access Catheters Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027) that is published by Future Market Insights, global vascular access catheters market to grow from US$ 2,365.3 Mn in 2017 to US$ 4,042.8 Mn by 2027 end. This represents CAGR of 5.5% over the projected period of 10-years.  The global vascular access catheters market for represents absolute $ opportunity of US$ 118.9 Mn in 2018 over 2017 and incremental opportunity of US$ 1,677.5 Mn between 2017 and 2027.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5327 

Global Vascular Access Catheters Market: Drivers

• Increased precision of PICC and CVC placement with tip location devices
• Improved Reimbursement policies
• Preference by surgeons, anaesthesiologists & interventional radiologists
• Increasing number of diseases with PICC application
• Distribution and collaboration agreement to increase product reach
• Introduction of Innovative products
• Product availability through appointing distributors
• Increasing forward integration
• Introduction of new PICC having anti-thrombogenic property
• Radiopaque catheter material or marking

Global Vascular Access Catheters Market: Forecast by Product

On the basis of product type, the global vascular access catheters market is segmented into CVC Catheters, Implantable Port, Dialysis Catheters and PICC Catheters. CVC catheters dominated the global market in 2016, and is expected to continue to do so. Also, increasing approvals for new products in the hemodialysis and peritoneal dialysis segment would further increase the adoption.

Global Vascular Access Catheters Market: Forecast by End Use

By end use the global market for vascular access catheters market is segmented into hospitals, ambulatory surgical centres and specialty clinics and others. Hospital is expected to be the most lucrative among all end users of vascular access catheters products, with attractiveness index of 2.7, while specialty clinics and others are expected to be the least attractive end users of vascular access catheters, with market share index of 0.8.

Global Vascular Access Catheters Market: Forecast by Design

Design segment consists of single lumen, double lumen, and multiple lumen. Double Lumen, dominated the vascular access catheters market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Double lumen catheters is expected to be the most lucrative among property segment, with attractiveness index of 2.1.

Global Vascular Access Catheters Market: Forecast by Property

The property segment of the global vascular access catheters market includes antimicrobial catheter and non-anti-microbial catheter. Non Anti-microbial catheter, dominated the vascular access catheters market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Non Anti-microbial Catheter is expected to be the most lucrative among Property segment, with attractiveness index of 1.5.

Global Vascular Access Catheters Market: Forecast by Region

This report has covered seven regions namely, North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan and MEA. North America vascular access catheters market accounted for largest revenue share of 44.6% in 2016. Western Europe is expected to experience highest CAGR of 5.8% over 2017–2027, primarily due to increase in chronic kidney dialysis & cancer. Also rising healthcare reach in untapped markets may spur revenue growth during the forecast period.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5327 

Global Vascular Access Catheters Market: Key Players

Some of the key players operating in the global vascular access catheters market are Angio Dynamics, C.R. Bard, Teleflex Incorporated, B. Braun Melsungen AG, Kimal Healthcare, Comed B.V., Medtronic Plc, Smiths Medical, Vygon (UK) Ltd, Becton, Dickinson and Company, Argon Medical Devices, Inc., Boston Scientific Corporation, Cook Medical Incorporated and Fresenius Kabi AG.

Endoscope Reprocessing Device Market Worth US$ 2,171.5 Mn by 2027

Global endoscope reprocessing device market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by growing geriatric population, increasing number of Endoscope surgeries and development of automated endoscope reprocessor and techniques. According to the new report, “Endoscope Reprocessing Device Market: Global Industry Analysis (2012–2016) and Opportunity Assessment (2017–2027),” which has been published by Future Market Insights for the projected period of 10-years, i.e. during 2017 to 2027, the endoscope reprocessing device market in MEA is expected to record comparatively less growth due to low awareness about infection control and less availability of reprocessor. The global endoscope reprocessing device market to grow from US$ 949.9 Mn in 2016 to US$ 2,171.5 Mn by 2027 end. This represents CAGR of 7.9% over the forecast period of 2017–2027

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2058 

Global Endoscope Reprocessing Device Market: Restraints

• Reported Adverse Events From Failure of Endoscope Reprocessing
• Excise duty imposed on medical device manufacturers would reduce profit margin
• High Cost of Technology Hampering the Growth of Endoscope Reprocessing Device Market
• Inadequate Reimbursement Policies Restrain the Market Growth
• Delayed Reprocessing and Lack of Clarity of Instruction
• Stringent Rules and Regulations
• Dearth of Trained Endoscopy Specialists and Professionals
• Poor Health Care System Hampering the Market growth
• Low Awareness of Endoscope Reprocessing in Developing Countries  are Hampering the  Market Growth
• Lack of Proper Healthcare Infrastructure In Emerging Markets
• Increase in Pricing Competition for Endoscope Reprocessing Device

Global Endoscope Reprocessing Device Market: Forecast by Product

Global endoscope reprocessing device market is categorized into automated endoscope reprocessor, washer disinfector, sterilizer, ultrasonic washer and drying and storage Cabinet. The study covers revenue generated by product type which includes, above mentioned product type. However, the study does not consider the revenue from which are not mentioned in the report. This report analyses installed base and new sale devices. Sterilizer and automated endoscope reprocessor segment dominated the global endoscope reprocessing device market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Sterilizer segment is expected to be the most lucrative among all product type, with attractiveness index of 1.6.

Global Endoscope Reprocessing Device Market: Forecast by End User

Endoscope reprocessing devices based on end user, the total installed base and new sale of endoscope reprocessing devices obtain from the three end user such as hospital, ambulatory surgical centre and specialty clinics. The study covers revenue generated by hospitals, ambulatory surgical centre and specialty clinics which includes, installed devices and new sale of devices. However, the study does not consider the revenue from which are not mentioned in the report.

Global Endoscope Reprocessing Device Market: Regional Analysis

As many as seven regions have been covered in this report, such as North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan, and MEA. If CAGR is considered, Latin America, Eastern Europe and APEJ have highest CAGRs throughout the forecasted period among all other regions. However, in terms of revenue North America and APEJ dominated the global endoscope reprocessing device market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America and APEJis expected to be the most lucrative among all regions, with attractiveness index of 2.1 and 1.7 respectively.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-2058 

Global Endoscope Reprocessing Device Market: Competitive Landscape

Medivators Inc., Olympus Corp., STERIS Plc., Getinge Group, Hoya Group, Laboratoires Anios, Custom Ultrasonics, Inc., SciCan Ltd (Sanavis Group), Shinva Medical Instrument co., Ltd., ARC Healthcare Solutions Inc., Antonio Matachana SA, Choyang Medical Industry Ltd., DGM Pharma-Apparate Handel Ag, MMM Medical Equipment UK LTD, Medonica Co. Ltd., Belimed AG (Metall Zug), Steelco S.P.A, and Advanced Sterilization Products Services Inc., are some of the key players operating in the global market for endoscope reprocessing device market.

Respiratory Inhaler Devices Market is estimated to expand at a CAGR of 4.2% during the forecast period 2017-2027

Future Market Insights delivers key insights and presents a revised forecast of the global respiratory inhaler devices market for a 10 year period from 2017 to 2027 in the report titled “Respiratory Inhaler Devices Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.” The revisions in the market size and forecasts have been carried out taking into account the impact of various macroeconomic indicators and other industry-based demand-driving factors, as well as the recent developments of key market participants. The global respiratory market is projected to expand at a healthy CAGR of 4.2% in terms of value during the forecast period, revised from the previous CAGR of 4.3%.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5331 

Market Dynamics

Increase in prevalence of asthma, COPD and other respiratory disorders, especially among paediatric and the geriatric population, is a major factor driving growth of the global respiratory inhaler devices market.

Other trends driving growth include strategic alliances among key players in the market, manufacturers focusing on enhancing market share, and expansion of the healthcare sector in developing countries due to growing investments by major players. In addition, surge in demand for respiratory inhaler devices in all acute and moderate asthma and COPD conditions owing to increasing health awareness and growing disposable income is projected to result in increased spending on respiratory inhaler devices. This in turn is expected to bolster respiratory inhaler devices market growth during the forecast period (2017–2027).

Lack of unique effective drugs for all types of respiratory symptoms, side effects and complications, lack of skilled pulmonologist and healthcare professionals, lack of awareness among the patients, together with high prices of inhaler devices are key factors hampering growth of this market. Currently combined therapies offer more associated benefits such as reliability in use for complex patients, increased efficacy and favourable reimbursement policies associated with the therapy. Hence, patients with complex respiratory disorders are more inclined towards adopting such therapies. However, the cost associated with combination therapies are higher as compared to conventional therapies for patients with complex respiratory disorders. The global respiratory inhaler devices market is expected to be driven by the increased usage of newly introduced triple combination therapy for COPD patients in the coming years.

Segmentation and Forecast

The market is segmented on the basis of product type, disease indications, technology and region. Based on the product segmentation, the overall market has been separated into metered dose inhaler (MDI), dry powder inhaler (DPI) and nebuliser. Nebulisers is further sub-segmented into ultrasonic nebuliser, mesh nebuliser and compressed air nebuliser. The metered dose inhaler segment is estimated to account for maximum share in the global respiratory inhaler devices market by 2017 end, and expected to register a CAGR of 4.5% in terms of value during the forecast period. Currently, metered dose inhaler is a major contributor to market growth in Europe, North America and parts of Asia Pacific. Nebuliser segment in the global market is expected to register a CAGR of 3.6% in terms of value during the forecast period.

The report has segmented the global respiratory inhaler devices market on the basis of region into North America, Western Europe, Eastern Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Middle East & Africa and Japan. This report assesses trends driving each segment and offers analysis and insights about the potential of respiratory inhaler devices market in specific regions. North America is estimated to dominate the respiratory inhaler devices market with maximum market share by end of 2017. North America and Western Europe are collectively expected to account for over 64.4% of the total respiratory inhaler devices market share in terms of value by end of 2017. Asia Pacific excluding Japan is estimated to witness highest CAGR of 4.5% over the forecast period, followed by North America, due to increasing prevalence of asthma and COPD among children and the geriatric population. Presence of key regional players, strong distribution network, and developed healthcare infrastructure are the key factors driving the growth of the market in North America.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5331 

Key Players

Some key companies covered in this report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Cipla Ltd., Koninklijke Philips N.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., OMRON Healthcare Europe B.V. and Merck & Co., Inc. Their primary focus is towards enhancing their product portfolio through research and development, introduction of innovative and cost-effective drugs and medical devices in order to gain market share and to strengthen their respective position in the global market.

Neuroendocrine Carcinoma Market Estimated to Exhibit 7.7% CAGR through 2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions in the globe. It has also included an in-depth analysis on the various key players participating in the global neuroendocrine carcinoma marketalong with key developments taking place during the 2017-2027 timeline. Future Market Insights, in its recent publication titled “Neuroendocrine Carcinoma Market: Global Industry analysis (2012-2016) and Opportunity Assessment (2017-2027)” has covered a holistic angle of the global market for neuroendocrine carcinoma with a detailed market segmentation. This research report also unveils various opportunities, trends, drivers and restraints impacting the growth of the global neuroendocrine carcinoma market. Covering past and present market scenario, the global report also gives justice to the readers’ investment in procuring the research report by giving future market projections for a period of ten years.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1278 

Global Neuroendocrine Carcinoma Market: Key Future Projections

The global neuroendocrine carcinoma market is anticipated to witness high growth during the period of forecast to reach a valuation of about US$ 2.5 Bn by the end of the forecasted year from an estimate of around US$ 1.5 Mn in 2017. This market is projected to grow at a high 7.7% CAGR throughout the forecast period.

Global Neuroendocrine Carcinoma Market: Key Influencing Aspects

There are several aspects influencing the growth of the neuroendocrine carcinoma market. Few growth pushing aspects include rising awareness campaigns by governments for early detection and treatment, rising number of clinical trials in early phase development, exploring new generation sequencing technologies, increasing partnerships to strengthen product portfolios, identifying new solutions to fight cancer, increasing investments in research and development and quick regulatory approvals prompting use of new therapeutic solutions. Also, high cost associated with the treatment of neuroendocrine carcinoma, high cost of development leading to reduction in the number of players participating in this market and manufacturing challenges adversely impacting the product availability are limiting the growth of the global market for neuroendocrine carcinoma.

Global Neuroendocrine Carcinoma Market: Segmental Acumen

The global neuroendocrine carcinoma market is segmented on the basis of disease indication type treatment type, end user and by region.

• By region, North America region is expected to be highly attractive for the neuroendocrine carcinoma market. The North America neuroendocrine carcinoma market is anticipated to grow at a significant rate to register the highest estimate by the end of the forecasted year thus leading the global market. Also, Asia Pacific excluding Japan (APEJ) neuroendocrine carcinoma market is projected to grow at the highest pace to register a stellar CAGR of 8.5% throughout the forecast period
• By disease indication type, the gastric neuroendocrine tumours segment is the largest segment in terms of market value as well as growth rate. This segment is estimated at a high value of US$ 1.2 Bn by 2027 end followed by the lung neuroendocrine tumours segment, that stands at the second position in the global market
• By treatment type, the somatostatin analogs segment is expected to dominate the global market with a high market valuation of a bit more than US$ 1.5 Bn by the end of the forecasted year, growing at a noteworthy growth rate during 2017-2027 timeline
• By end user, hospitals segment is anticipated to the largest segment leading the global neuroendocrine carcinoma market with a high CAGR of 8.2% during the period of assessment, owing to high infrastructure investment towards adopting newer detection technologies. The clinics segment also reflects high potential in the years to come

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1278 

Global Neuroendocrine Carcinoma Market: Competitive Scenario

The global neuroendocrine carcinoma market research report has included key players involved in the market. The SWOT analysis, product portfolio, developments, strategies, key financials and other key details of companies such as Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Advanced Accelerator Applications, Mateon Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Isotopen Technologien München AGGlobal, Hutchison China MediTech Ltd., Amgen Inc., Celgene Corporation, Mallinckrodt plc., and Dauntless Pharmaceuticals, Inc., is included in this extensive research study.

Keloid Treatment Market to Reach a Valuation of US$ 4,414.6 Mn By 2027

According to the latest market report published by Future Market Insights titled‘Keloid Treatment Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027),’the global keloid treatment market is estimated to be worth US$ 3,145.8 Mn by 2017 end, and is expected to expand at a CAGR of 3.4% over the forecast period of 2017–2027 to reach a market valuation of US$ 4,414.6 Mn by the end of 2027.

Global Keloid Treatment Market: Dynamics

The global keloid treatment market growth is substantially driven by the rising prevalence of keloid scars as well as the development of multiple keloids. A growing consciousness among patients regarding their appearance is also driving the market of keloid treatment as keloid scars on the exposed body parts leads to ugly appearances. Other factors that are driving the growth in the keloid treatment market include increasing reimbursement for keloid therapies, formalisation of standard treatment guidelines for keloid and increasing use of combination therapies. Clinics and hospitals are focussing on the adoption of advanced therapy options. CryoShape is used to reduce the impact of keloid scar and recurrence rate. Sensus Healthcare has developed an advanced superficial radiation therapy device to impart better treatment with limited adverse reactions.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1313 

Global Keloid Treatment Market: Segmental Forecast

The global keloid treatment market is segmented based on treatment type, end user and region. On the basis of treatment type, the market has been segmented intoocclusive dressing, compression therapy, cryosurgery, excision, radiation therapy, laser therapy, interferon therapy, intralesional corticosteroid injection and others. Other treatment options include dermal fillers, topical creams, 5-fluorouracil, retinoic acid and imiquimod. Intralesional corticosteroid injection treatment segment dominates the global keloid treatment market as this procedure is considered the gold standard and is being used in combination with other therapies. Intralesional corticosteroid injection is expected to be the second most lucrative segment by treatment type, with a market attractiveness index of 2.1 during the forecast period.

Based on end user, the global keloid treatment market is segmented into hospitals, dermatology clinics, ambulatory surgical centres and others. Thehospitals segment is expected to remain dominant, as most of the radiation therapies and excision procedures are performed in hospitals. Hospitals is the largest segment by end user, which is estimated to represent US$ 1,164.7 Mn, or 37.0% share of the total market in 2017 and is projected to reach a market valuation of US$ 1,643.8 Mn, or 37.2% share of the total market by the end of 2027, expanding at a CAGR of 3.5% in terms of value.

Global Keloid Treatment Market: Regional Analysis

On the basis of region, the global keloid treatment market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and the Middle East & Africa.

North America dominated the global keloid treatment market in 2016 and is expected to continue to dominate the global market throughout the forecast period. North America is the largest region in keloid treatment market, which is estimated to represent US$ 1,105.6 Mn, or 35.1% share of the total market in 2017 and is projected to reach a market valuation of US$ 1,549.6 Mn, or 35.1% of the total market by the end of 2027, expanding at CAGR of 3.4% in terms of value. Clinics in North America are opting advanced treatment therapies that can aid in reduced risk of recurrence.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1313 

Global Keloid Treatment Market: Vendor Analysis

Leading players in the global keloid treatment market are launching new portable and mobile radiation therapy devices and are offering better treatment options to patients. Companies are targeting dermatology clinics to market their devices, where patients are provided the first line of treatment for keloid. Some of the players operating in the global keloid treatment market who have been profiled in the report include Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation and Avita Medical Limited.

Continuous Peripheral Nerve Block Catheter Market will Exhibit a Steady 6.1% CAGR through 2027

Future Market Insights has delivered key insights and presented a revised forecast analysis on continuous peripheral nerve block catheters market in its new research study titled “Continuous Peripheral Nerve Block Catheter Market: Global Industry Analysis (2012-2016) and Forecast (2017-2027)”. Continuous peripheral nerve block catheter are increasingly being used for pain management in patients undergoing upper/lower extremity surgeries and patients suffering from trauma, owing to their advantages, such as meticulous precision and low-price. Continuous peripheral nerve block catheter are emerging as a credible alternative to opioids for pain management as ill-effects associated with opioids are very severe such as addiction to opioids

Global Continuous Peripheral Nerve Block Catheter Market: Forecast Highlights

The global continuous peripheral nerve block catheter market is anticipated to record a CAGR of 6.1% and the market is estimated to reach a value of US$ 742.7 Mn in 2027 from a valuation of around US$ 411 Mn in 2017.

Global Continuous Peripheral Nerve Block Catheter Market: Segmental Analysis

The market is segmented based on product type, insertion technique, indication, end users and regions. On the basis of product type, the market has been segmented into stimulating catheter system, non-stimulating catheter systems and over-the-needle catheter systems. Non-stimulating catheter systems segment dominated the global continuous peripheral nerve block catheter market in terms of value and volume in 2017. This segment is expected to continue its dominating streak throughout the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1307

On the basis of insertion technique, the continuous peripheral nerve block catheter market has been segmented into nerve stimulation and ultrasound based insertion technique. Continuous peripheral nerve block catheter that uses ultrasound based insertion technique is expected to witness higher demand than devices that use nerve stimulation technique for catheter insertion. The ultrasound based insertion technique segment is projected to grow at a higher rate during the forecast period. However, the nerve stimulation based insertion technique segment is expected to show a higher market valuation.

On the basis of indication, the continuous peripheral nerve block catheter market has been segmented into trauma cases, upper extremity surgeries, lower extremity surgeries, pain management and other indications. Amongst these aforementioned segments, lower extremity surgeries segment is expected to witness higher revenue growth as compared to other segments over the forecast period and this segment is expected to show higher value CAGR throughout the period of assessment.

Key end-use sectors that generate the bulk of demand for continuous peripheral nerve block catheter can be broadly categorised into hospitals and ambulatory surgical centres. Among these, hospitals account for the largest revenue share of the market, owing to increasing number of hospitalisations for upper/lower extremity procedures carried out in hospitals. The hospital segment is a highly lucrative segment from an investment standpoint.

FMI’s report has segmented the global continuous peripheral nerve block catheter market on the basis of region into North America, Western Europe, Eastern Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Middle East & Africa and Japan. This report assesses trends driving each market segment and offers analysis and insights about the potential of continuous peripheral nerve block catheter in specific regions. The North America region is the leading region in terms of global revenue share, followed by Western Europe and Japan. North America is estimated to dominate the continuous peripheral nerve block catheter market with maximum value share of the overall market by end of 2017. North America continuous peripheral nerve block catheter market increase at a CAGR of 6.5% through 2027. Presence of key regional players, strong distribution network, and developed healthcare infrastructure are the key factors driving the growth of the market in North America.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1307

Global Continuous Peripheral Nerve Block Catheter Market: Competitive Assessment

Some key players in the global continuous peripheral nerve block catheter market identified include B. Braun Melsungen AG, Teleflex Incorporated, Halyard Health, Inc., Epimed International Inc. and Pajunk GmbH.

Silent Scan Technology Market Greater Revenue Share by 2026

Adoption of silent scan technology continues to face major challenges, with high cost and a general lack of awareness being the key restraints, according to a new survey by Future Market Insights (FMI). The survey was conducted among respondents from 300 global healthcare facilities, spanning sectors in North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa (MEA), Asia Pacific excluding Japan (APEJ), and Japan. Majority of the respondents in the survey were from the U.S., Canada, Germany, the U.K., the Netherlands, Belgium, Australia, Saudi Arabia and the U.A.E. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1623

Although 44% of responding healthcare facilities currently own an MRI machine with silent- or soft-scan technology, a majority of them were averse to installing one in the future. In addition to high cost of silent scan MRIs and lack of awareness, respondents cited absence of distribution facility and insufficiency of technology as other key factors for not having an MRI machine with silent scan technology.

“Silent scan technology is at a nascent stage globally, and although it serves as an effective model for reducing decibel levels, high cost continues to impede its widespread adoption,” said Vrishali Bhagwat, FMI consultant, and co-author of the report Silent Scan Technology Market - Emergence of Private Hospitals Segment as the Most Prominent End User is a Key Factor Driving Revenue Growth. “However, the future looks promising for the technology, as there’s an overall appreciation of the technology, especially among end-users in the private hospitals segment. As technology makes a headway and prices become competitive, adoption is expected to pick up globally.”

FMI’s survey found that adoption varied widely based on the type of healthcare setting. While hospitals are the leading end-users, respondents in private hospitals are more receptive towards the adoption of silent scan technology. Satisfaction with the overall effectiveness of silent scan MRIs is exceedingly high and there’s a sense of understanding that silent scan MRIs do what they promise—quiet, noise-free MRI scans. “Silent scan MRIs received a higher rating than their noisy counterparts from respondents, and this represents an underlying sentiment that the technology per se isn’t the root cause for slow adoption,” added Vrishali.

According to FMI’s market forecast report, silent scan installation base is anticipated to reach 1,815 units in 2016, up from 1,015 units in 2015. Silent scanners constituted 1% of total MRI machine installations in 2015, and owing to their positive reception among end-users, their adoption is expected to witness a steady increase during the forecast period.

Hospitals are the leading end-use segment in the global silent scan technology market, and are expected to account for nearly 50% volume share of the market in 2016. Regionally, North America and Asia Pacific excluding Japan (APEJ) are the two largest markets, accounting for over 50% share of the global market in terms of volume. The market in these two regions is dominated by the U.S. and China respectively.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1623

FMI’s report forecasts the global silent scan technology market to increase at a steady compound annual growth rate (CAGR) of 5.4% through 2026.

Urinary Tract Infection Treatment Market will Exhibit a Steady 2.1% CAGR through 2026

There has been an increasing prevalence of the urinary tract infection followed by which, greater emphasis is given to the urinary tract infection treatment for effective control of the incidents of the spreading urinary tract infections. The global analysis presented in the research study conducted by Future Market Insights (FMI), projects that the global urinary tract infection treatment market revenue is projected to grow at a CAGR of 2.1% during the forecast period from 2016 to 2026. The urinary tract infection treatment market is expected to account for over US$ 11,585.9 million by the end of 2026, owing to major changes projected by the market. Although the market projects a sluggish growth, the growing awareness of the urinary tract infection treatment further supported by favorable incentives and policies of reimbursements are expected to nurture the urinary tract infection treatment market throughout the period of assessment.

Regulatory requirements and declining investments in research are expected to lead the market towards a low CAGR. Complex clinical trials have resulted in a declining focus towards research and development by the major companies. Moreover, the sale of drugs and medication prescribed for the urinary tract infection treatment is seen declining as the patients suffering from urinary tract infection are symptom-free for an initial week or two, unlike the chronic diseases.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Despite the setbacks, the growth of the urinary tract infection treatment market is expected to be predominantly triggered by the growing prevalence of urinary tract infections followed by the new medication and drugs prescribed for the urinary tract infection treatment. The stagnancy in the urinary tract infection treatment market is expected to be aided by new and improved drugs and medical breakthroughs that would redefine the future of the urinary tract infection treatment market. New improvements introduced to the urinary tract infection treatment market are expected to assist the market in effective recovery from the modest growth rate. Researchers have developed new antibiotics for fighting the urinary tract infections. The United States Food and Drug Administration (FDA) has approved the use of the antibiotic plazomicin for the treatment of complex urinary tract infections. Even though it is not a new antibiotic, plazomicin has been developed by the United States biotech Achaogen to treat infections.

Owing to the growing consumption of antibiotics in the BRICS countries, these regions are the most promising regions for the urinary tract infection treatment market. Amongst other regional markets stated in the research study, the APEJ market is projected to reach US$ 4,400.5 million in terms of revenue. As the consumption of antibiotics is highest in China and India owing to the rising disposable income in these countries, the APEJ region is expected to register a fastest growth rate of 2.4 percent in terms of market value over the forecast period.

The rising number of urinary tract infection patients across the globe owing to the urinary tract infection’s contribution to the second-largest patient pool in the world, there are a number of generic antibiotic drugs made available for the urinary tract infection treatment. This factor has changed the global scenario of the health-care and pharmaceutical industry. Major market players such as Cipla, GlaxoSmithKline, and Pfizer are seen investing in antibacterial discovery programs for an improved treatment of the urinary tract infection. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1340

Moreover, the major participants are focusing on contributing enhanced drugs to the urinary tract infection treatment market by involving in collaborations and focusing on extended research to cater to the unmet needs of the urinary tract infection patients. The market players such as Johnson & Johnson Private Ltd. are seen implementing expansion strategies for spreading their operations in leading markets such as China, India, and Brazil for growing their business as the sales are slow in matured markets in regions including the United States and Europe.

Digital Mobile X-Ray Devices Market Attractive Market Opportunities in the by 2026

Future Market Insights, in its latest research, delivers key insights on the factors impacting the global digital mobile X-ray device market. According to the report, demand for digital mobile X-ray devices will continue to be fuelled by applications in orthopaedic- and chest-imaging. These two end-use applications accounted for 60% revenue share of the market in 2016.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-990 

Key Driving Factors

• Increasing emphasis on diagnostic imaging services by various government bodies.
• Increasing geriatric population – according to WHO, global geriatric population will reach 2 billion by 2050
• Rising incidences of orthopaedic diseases and bone injuries – WHO estimates global prevalence of arthritis to between 0.3% and 1%
• Contractual agreements and acquisitions by manufacturers
• Increasing adoption of 3D medical imaging equipment, especially in the field of orthopaedics
• Increase in the number of free standing imaging centers

Key Restraints

• High cost of clinical trials and stringent regulations have remained longstanding challenges for manufacturers
• Lack of inadequate imaging infrastructure in developing countries. High cost associated with initial set up and installation has been identified as a major restraint
• Increasing pressure on the healthcare budget in the U.S. and rising awareness among patients about the potential health impact of radiation

By product type, mobile devices will continue to outsell handheld devices. In 2016, of the US$ 7.67 Bn worth of digital X-ray devices sold, 91.5% were mobile devices. However, owing to their small base size, demand for handheld digital mobile X-ray devices will grow at a higher CAGR than mobile devices.

Hospitals and radiology centers will continue to be the leading end-users of digital mobile X-ray devices globally. These two end-users collectively accounted for nearly 70% revenue share of the market in 2016. According to Future Market Insights’ research, these two end-use sectors will continue to account for the bulk of demand for digital mobile X-ray markets during the forecast period.

Region-wise Analysis and Forecast

• North America is the largest market for digital mobile X-rays globally. Demand for digital mobile X-ray devices in the region is fuelled by strong sales in the U.S.
• North America’s revenue share of the global market was nearly 32% in 2016. Owing to increasing demand in Asia Pacific excluding Japan (APEJ), Latin America, and Japan, North America will witness a slight dip in revenue share over the forecast period.
• APEJ is projected to be the fastest growing market for digital mobile X-ray devices globally. The market in the region is expected to grow on account of high volume demand from China and India.
• The Eastern Europe digital mobile X-ray market will witness slowest growth among all regions.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-990 

Competitive Landscape Analysis

Leading companies in the global digital mobile X-ray devices market are General Electric Healthcare Limited, Siemens AG, Esaote SpA, Hitachi Ltd., Koninklijke Philips N.V, Planmed OY, EOS Imaging, and Toshiba Medical Corporation. These leading companies are eyeing the lucrative APEJ market to capitalise on the growing opportunities. Future Market Insights maintains a positive outlook on the global digital mobile X-ray market, projecting it to grow at 7.1% CAGR through 2026.

Digital Breast Tomosynthesis (DBT) Equipment Market Promising Growth Opportunities over 2016 to 2026

Digital breast tomosynthesis (DBT) or 3-D mammography new installations (includes new equipment and 3-D upgradation) expected to reach 4,547 units in 2016, up from 4,061 units in 2015. In terms of revenues, the global digital breast tomosynthesis equipment market is expected to reach 1,007.6 Mn in 2016, witnessing a year-over-year growth of 13.7%. 

Limitations concerning the flat nature of images achieved through a 2-D full-field digital mammography (FFDM) is influencing end-users to adopt DBT equipment for diagnosis of breast cancers. Digital breast tomosynthesis enables radiologists to analyse abnormalities lucidly, helping improve detection rates while reducing callbacks. In the backdrop of these factors, demand for digital breast tomosynthesis equipment is witnessing an uptick, and the trend is expected to gain further momentum in the future.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1241

Sales of DBTs have remained quite robust in the US in the recent past, making North America the most lucrative market globally. The market in the region is largely dominated by Hologic, Inc. although GE and Siemens Healthineers have also registered their presence by launching innovative DBT products at competitive prices. Total DBT equipment revenues in North America were pegged at 472.8 Mn in 2015, with the U.S. accounting for bulk of revenue share. New equipment installation base in North America is expected to reach 2,327 in 2016, up from 2,066 in 2015.

In addition to North America, digital breast tomosynthesis sales are also growing steadily in Western Europe and APEJ. Revenues in Western Europe are anticipated to grow by 13.4% in 2016, whereas APEJ is expected to increase at 12.2%.

By end-users, hospitals account for higher demand for DBTs vis-à-vis diagnostic centres. Many hospitals are in the process of upgrading their existing mammography machines, owing to which demand for DBT equipment is growing at a steady rate. However, high costs, coupled with lack of awareness can impede adoption rates in both hospitals and diagnostic centres, and slow down the growth of the market globally. Installations of DBTs in hospitals totalled 3,020 in 2015, representing a market value worth 542.8 Mn.

Key players in the global digital breast tomosynthesis equipment market include Hologic Inc., GE Healthcare, Siemens Healthineers, Internazionale Medico Scientifica, Fujifilm, and Planmed Oy. The top 3 players - Hologic, Inc., GE Healthcare, and Siemens Healthineers collectively account for nearly 90% revenue share of the market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1241

Long-term Outlook: In terms of revenues, the global tomosynthesis equipment market is expected to increase at 13.9% CAGR during the forecast period 2016-2026. Total installations of DBT equipment are anticipated to reach 17,700 units.

Veterinary Vaccines Market to Gain a Stronghold by 2026

Demand for veterinary vaccines is witnessing an increase, as focus shifts from cure to prevention among farm- and pet- owners. The global pet humanisation trend is massively influencing demand for veterinary healthy products and services, and vaccines are riding on the coattails of this trend. The global veterinary vaccines market is anticipated to reach US$ 7.24 Bn in 2016, up from US$ 6.82 Bn in 2015.

Focus on improving food security and mitigating the spread of contagious diseases will continue to fuel demand for veterinary vaccines. Increase in foodborne and zoonotic diseases has adversely affected animal production in the recent past, owing to which emphasis on maintaining health and well-being of animals has gained prominence.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-409

On the basis of product type, attenuated live vaccines will continue to hold the leading revenue share, closely followed by inactivated vaccines. These two product segments accounted for nearly 47% revenue share of the market in 2015, and are expected to dominate global revenues in 2016 as well.

By disease type, foot and mouth disease and anaplasmosis are the two largest segments, collectively accounting for over US$ 2.1 Bn in revenues in 2015. Canine parvovirus is another key disease type, contributing significant revenues to the global market.

Veterinary clinics remain the most prominent distribution channel for veterinary vaccines, and accounted for nearly 40% revenue share of the market in 2015. Veterinary clinics sold US$ 2.74 Bn worth of veterinary vaccines in 2015, and this figure is expected to reach US$ 2.91 Bn in 2016.

By animal type, livestock animals accounted for bulk of the demand for veterinary vaccines in 2015, and the status quo is anticipated to remain unchanged in the future as well. Companion animals are further segmented into canine, avian, and feline, of which, canine segment accounted for the bulk of the revenues in 2015.

North America and Western Europe are the two largest markets for veterinary vaccines, collectively accounting for over 57% revenue share of the market in 2015. The market in North America is dominated by the U.S., which accounted for US$ 1.58 Bn in revenues in 2015. The Canada veterinary vaccines market is expected to surpass US$ 500 Mn in revenues in 2016. Outside of North America, Western Europe and Asia Pacific excluding Japan (APEJ) are the leading markets for veterinary vaccines.

Request for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-409

Key players in the global veterinary vaccines market include Merial, Zoetis, Elanco, Merck & Co. Inc, Boehringer Ingelheim GmbH (BIVI), Bayer Pharma AG, Ceva, Virbac, Diamond Animal Healthcare (Heska) and Indian Immunological Ltd.